A Phase I Clinical Trial of Hepatic Arterial Infusion of Oxaliplatin, Oral Capecitabine, With or Without Systemic Bevacizumab for Patients With Advanced Cancer Metastatic to the Liver.

Trial Profile

A Phase I Clinical Trial of Hepatic Arterial Infusion of Oxaliplatin, Oral Capecitabine, With or Without Systemic Bevacizumab for Patients With Advanced Cancer Metastatic to the Liver.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Cancer; Colorectal cancer; Liver cancer; Liver metastases; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jun 2018 Results (n=61) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 14 Mar 2018 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.
    • 08 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top